Chemotherapy regimen

Regimen commonly used in chemotherapy

A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via cytotoxicity.

A fundamental philosophy of medical oncology, including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be synergistic to some extent. Because they have different dose-limiting adverse effects, they can be given together at full doses in chemotherapy regimens.[1]

The first successful combination chemotherapy was MOPP, introduced in 1963 for lymphomas.

The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A "maintenance regimen" refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow.[2]

## Nomenclature

[edit]

Chemotherapy regimens are often identified by acronyms, identifying the agents used in the drug combination. However, the letters used are not consistent across regimens, and in some cases - for example, "BEACOPP" - the same letter combination is used to represent two different treatments.[3]

There is no widely accepted naming convention or standard for the nomenclature of chemotherapy regimens. For example, either generic or brand names may be used for acronyms. This page merely lists commonly used conventions.

## List of chemotherapy regimen acronyms

[edit]

Name | Components | Example of uses, and other notes

|
|

7+3, also known as DA or DAC in case of daunorubicin, or IA or IAC in case of idarubicin use  | 7 days of Ara-C (cytarabine) plus 3 days of an anthracycline antibiotic, either daunorubicin (DA or DAC variant) or idarubicin (IA or IAC variant)  | Acute myelogenous leukemia, excluding acute promyelocytic leukemia
ABVD | doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine | Hodgkin's lymphoma
AC  | doxorubicin (Adriamycin), cyclophosphamide | breast cancer
BACOD  | bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone | Non-Hodgkin lymphomas
BEACOPP | bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone | Hodgkin's lymphoma
BEP  | bleomycin, etoposide, platinum agent | testicular cancer, germ cell tumors
CA  | cyclophosphamide, doxorubicin (Adriamycin) (same as AC)  | breast cancer
CAF  | cyclophosphamide, doxorubicin (Adriamycin), fluorouracil (5-FU)  | breast cancer
CAPOX or XELOX  | capecitabine and oxaliplatin | colorectal cancer
CAV  | cyclophosphamide, doxorubicin (Adriamycin), vincristine | lung cancer
CBV | cyclophosphamide, BCNU (carmustine), VP-16 (etoposide)  | lymphoma
CHOEP | cyclophosphamide, hydroxydaunorubicin (doxorubicin), etoposide, vincristine (Oncovin), prednisone | Non-Hodgkin lymphomas
CEPP | cyclophosphamide, etoposide, procarbazine, prednisone | Non-Hodgkin Lymphomas
ChlVPP/EVA  | chlorambucil, vincristine (Oncovin), procarbazine, prednisone, etoposide, vinblastine, doxorubicin (Adriamycin)  | Hodgkin's lymphoma
CHOP | cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine (Oncovin), prednisone | non-Hodgkin lymphoma
CHOP-R or R-CHOP | CHOP \+ rituximab | B cell non-Hodgkin lymphoma
ClaPD  | clarithromycin, pomalidomide, dexamethasone | multiple myeloma
CMF | cyclophosphamide, methotrexate, fluorouracil (5-FU)  | breast cancer
CMV  | cisplatin, methotrexate, vinblastine | transitional bladder carcinoma
COP or CVP | cyclophosphamide, Oncovin (vincristine), prednisone | non-Hodgkin lymphoma in patients with history of cardiovascular disease
COPP | cyclophosphamide, Oncovin (vincristine), procarbazine, prednisone | Hodgkin's lymphoma
CT or TC  | docetaxel (Taxotere), cyclophosphamide | breast cancer
CTD  | cyclophosphamide, thalidomide, dexamethasone | AL amyloidosis
CVAD and Hyper-CVAD | cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone | aggressive non-Hodgkin lymphoma, lymphoblastic lymphoma, some forms of leukemia
CVE  | carboplatin, vincristine, etoposide  | retinoblastoma
CYBORD  | cyclophosphamide, bortezomib, dexamethasone | multiple myeloma, AL amyloidosis
DA or DAC | daunorubicin x 3 days plus ara-C (cytarabine) x 7 days, a variant of 7+3 regimen  | Acute myeloid leukemia, excluding acute promyelocytic leukemia
DAT | daunorubicin, cytarabine (ara-C), tioguanine | Acute myeloid leukemia
DCEP  | dexamethasone, cyclophosphamide, etoposide, platinum agent | relapsed or refractory multiple myeloma
DHAP | dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent | Non-Hodgkin lymphomas
DHAP-R or R-DHAP | dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab | Non-Hodgkin lymphomas
DICE  | dexamethasone, ifosfamide, cisplatin, etoposide (VP-16)  | aggressive relapsed lymphomas, progressive neuroblastoma
DT-PACE | dexamethasone, thalidomide, platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide | multiple myeloma
EC  | epirubicin, cyclophosphamide | breast cancer
ECF (MAGIC)  | epirubicin, cisplatin, fluorouracil (5-FU)  | gastric cancer and cancer of the esophagogastric junction (Siewert classification III)
EOX  | epirubicin, oxaliplatin, capecitabine | esophageal Cancer, gastric Cancer
EP  | etoposide, platinum agent | testicular cancer, germ cell tumors
EPOCH | etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin | Non-Hodgkin lymphomas
EPOCH-R or R-EPOCH | etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin plus rituximab | B cell Non-Hodgkin lymphomas
ESHAP | etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent | Non-Hodgkin lymphoma
ESHAP-R or R-ESHAP | etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab | Non-Hodgkin lymphoma
FAM  | fluorouracil, doxorubicin (Adriamycin), mitomycin | gastric cancer
FAMTX  | fluorouracil, doxorubicin (Adriamycin), methotrexate | gastric cancer
FCM or FMC | fludarabine, cyclophosphamide, mitoxantrone | B cell non-Hodgkin lymphoma
FCM-R or R-FCM or R-FMC or FMC-R | fludarabine, cyclophosphamide, mitoxantrone plus rituximab | B cell non-Hodgkin lymphoma
FCR  | fludarabine, cyclophosphamide, rituximab | B cell non-Hodgkin lymphoma
FM | fludarabine, mitoxantrone | B cell non-Hodgkin lymphoma
FM-R or R-FM or RFM or FMR | fludarabine, mitoxantrone, and rituximab | B cell non-Hodgkin lymphoma
FEC  | fluorouracil (5-FU), epirubicin, cyclophosphamide | breast cancer
FEC-T  | fluorouracil (5-FU), epirubicin, cyclophosphamide together, followed by docetaxel (Taxotere)  | breast cancer
FL (also known as Mayo)  | fluorouracil (5-FU), leucovorin (folinic acid)  | colorectal cancer
FLAG | fludarabine, cytarabine, G-CSF | relapsed or refractory acute myelogenous leukemia
FLAG-Ida or FLAG-IDA or IDA-FLAG or Ida-FLAG | fludarabine, cytarabine, idarubicin, G-CSF | relapsed or refractory acute myelogenous leukemia
FLAG-Mito or FLAG-MITO or Mito-FLAG or MITO-FLAG or FLANG[citation needed] | mitoxantrone, fludarabine, cytarabine, G-CSF | relapsed or refractory acute myelogenous leukemia
FLAMSA | fludarabine, cytarabine, amsacrine | myelodysplastic syndrome, acute myeloid leukemia
FLAMSA-BU or FLAMSA-Bu | fludarabine, cytarabine, amsacrine, busulfan | myelodysplastic syndrome, acute myeloid leukemia
FLAMSA-MEL or FLAMSA-Mel | fludarabine, cytarabine, amsacrine, melphalan | myelodysplastic syndrome, acute myeloid leukemia
FLOT | fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, docetaxel | esophageal cancer, gastric cancer
FOLFIRI | fluorouracil (5-FU), leucovorin (folinic acid), irinotecan | colorectal cancer
FOLFIRINOX | fluorouracil (5-FU), leucovorin (folinic acid), irinotecan, oxaliplatin | pancreatic cancer
FOLFOX | fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin | colorectal cancer
GC  | gemcitabine, cisplatin gemcitabine, dexamethasone, and cisplatin  | bladder cancer
GDP  | gemcitabine, dexamethasone, cisplatin | Non-Hodgkin lymphomas and Hodgkin lymphoma
GemOx or GEMOX | gemcitabine, oxaliplatin | Non-Hodgkin lymphomas
GVD | gemcitabine, vinorelbine, pegylated liposomal doxorubicin | Hodgkin lymphoma
GemOx-R or GEMOX-R or R-GemOx or R-GEMOX | gemcitabine, oxaliplatin, rituximab | Non-Hodgkin lymphomas
IA or IAC | idarubicin x 3 days plus Ara-C (cytarabine) x 7 days, a variant of classical 7+3 regimen  | Acute myelogenous leukemia, excluding acute promyelocytic leukemia
ICE | ifosfamide, carboplatin, etoposide (VP-16)  | aggressive lymphomas, progressive neuroblastoma
ICE-R or R-ICE or RICE | ICE \+ rituximab | high-risk progressive or recurrent lymphomas
IFL | irinotecan, leucovorin (folinic acid), fluorouracil | colorectal cancer
IVA  | ifosfamide, vincristine, actinomycin D  | rhabdomyosarcoma
MAP or MAPIE  | Doxorubicin (Adriamycin), Cisplatin, Methotrexate, Ifosfamide (Ifex), Etoposide (Vepesid)  | Bone cancer, Osteosarcoma
m-BACOD  | methotrexate, bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone | non-Hodgkin lymphoma
MACOP-B  | methotrexate, leucovorin (folinic acid), doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), prednisone, bleomycin | non-Hodgkin lymphoma
MAID  | mesna, doxorubicin, ifosfamide, dacarbazine | soft-tissue sarcoma
MINE | mesna, ifosfamide, novantrone, etoposide | Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases
MINE-R or R-MINE | mesna, ifosfamide, novantrone, etoposide plus rituximab | Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases
MMM  | mitomycin, methotrexate, mitoxantrone | breast cancer
MOPP | mechlorethamine, vincristine (Oncovin), procarbazine, prednisone | Hodgkin's lymphoma
MVAC  | methotrexate, vinblastine, doxorubicin (Adriamycin), cisplatin | advanced bladder cancer[4]
MVP  | mitomycin, vindesine, cisplatin | lung cancer and mesothelioma
NP  | cisplatin, vinorelbine | non-small cell lung carcinoma
PACE  | platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide |
PCV  | Procarbazine, CCNU (lomustine), vincristine | brain tumors
PEB  | cisplatin, etoposide, bleomycin | non-seminomatous germ cell tumors
PEI  | cisplatin, etoposide, ifosfamide | small-cell lung carcinoma
platin \+ taxane[5] | cisplatin/carboplatin, paclitaxel/docetaxel | ovarian cancer
POMP  | 6-mercaptopurine (Purinethol), vincristine (Oncovin), methotrexate, and prednisone | acute adult leukemia[6]
ProMACE-MOPP  | methotrexate, doxorubicin (Adriamycin), cyclophosphamide, etoposide \+ MOPP | non-Hodgkin lymphoma
ProMACE-CytaBOM  | prednisone, doxorubicin (Adriamycin), cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine (Oncovin), methotrexate, leucovorin | non-Hodgkin lymphoma
RdC  | lenalidomide (Revlimid), dexamethasone, cyclophosphamide | AL amyloidosis
R-Benda  | rituximab \+ bendamustine | follicular lymphoma and MALT lymphoma[7]
R-DHAP or DHAP-R | rituximab \+ DHAP; that is, rituximab, dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent | relapsed non-Hodgkin's lymphoma and Hodgkin's lymphoma
R-FCM or FCM-R | rituximab \+ FCM; that is, rituximab, fludarabine, cyclophosphamide, mitoxantrone | B cell non-Hodgkin lymphoma
R-ICE or ICE-R or RICE | rituximab \+ ICE; that is, rituximab, ifosfamide, carboplatin, etoposide | high-risk progressive or recurrent lymphomas
RVD  | lenalidomide (Revlimid), bortezomib, dexamethasone |
Stanford V | doxorubicin (Adriamycin), mechlorethamine, bleomycin, vinblastine, vincristine, etoposide, prednisone | Hodgkin lymphoma
TAC or ACT  | docetaxel (Taxotere) or paclitaxel (Taxol), doxorubicin (Adriamycin), cyclophosphamide | breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic)
TAD  | tioguanine, cytarabine (ara-C), daunorubicin | acute myeloid leukemia
TC or CT  | docetaxel (Taxotere), cyclophosphamide | breast cancer
TCH | docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin)  | breast cancer with positive HER2/neu receptor
TCHP  | docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin), pertuzumab (Perjeta)  | breast cancer with positive HER2/neu receptor
Thal/Dex  | thalidomide, dexamethasone | multiple myeloma
TIP  | paclitaxel (Taxol), ifosfamide, platinum agent cisplatin (Platinol)  | testicular cancer, germ cell tumors in salvage therapy
EE-4A | vincristine, actinomycin[8] | Wilms' tumor[8]
DD-4A | vincristine, actinomycin, doxorubicin (Adriamycin)[8] | Wilms' tumor[8]
VABCD  | vinblastine, doxorubicin (Adriamycin), bleomycin, lomustine (CeeNU), dacarbazine | MOPP refractory Hodgkin's Lymphoma
VAC  | vincristine, actinomycin, cyclophosphamide | rhabdomyosarcoma
VAD  | vincristine, doxorubicin (Adriamycin), dexamethasone | multiple myeloma
VAMP | one of 3 combinations of vincristine and others  | Hodgkin's lymphoma, leukemia, multiple myeloma
Regimen I | vincristine, doxorubicin (Adriamycin), etoposide, cyclophosphamide | Wilms' tumor[8]
VAPEC-B  | vincristine, doxorubicin (Adriamycin), prednisone, etoposide, cyclophosphamide, bleomycin | Hodgkin's lymphoma
VDC-IE  | vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide | Ewing's sarcoma
VD-PACE  | bortezomib, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide | multiple myeloma
VIFUP  | vinorelbine, cisplatin, fluorouracil | locally advanced/metastatic breast cancer
VIP  | vinblastine, ifosfamide, platinum agent, (etoposide (VP-16) may substitute for vinblastine, making a regimen sometimes referred to as VIP-16)[9][10] | testicular cancer, germ cell tumors
VTD-PACE  | bortezomib (Velcade), thalidomide, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide | multiple myeloma
V-DCEP  | bortezomib (Velcade), dexamethasone, cyclophosphamide, etoposide, platinum agent | relapsed or refractory multiple myeloma

## See also

[edit]

* National Comprehensive Cancer Network Treatment Guidelines
* Breast cancer chemotherapy
* High-dose chemotherapy
* Sequential high-dose chemotherapy

## References

[edit]

1. ^ Mayer RJ (February 2009). "Targeted therapy for advanced colorectal cancer—more is not always better". N Engl J Med. 360 (6): 623–5\. doi:10.1056/NEJMe0809343. PMID 19196680. letter commenting on the Clinical trial: Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ (February 2009). "Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer". N Engl J Med. 360 (6): 563–72\. doi:10.1056/NEJMoa0808268. hdl:2066/79995. PMID 19196673.
2. ^ "Cancer.net - Explaining Maintenance Therapy". Archived from the original on 2013-11-20. Retrieved 2012-08-16.
3. ^ BEACOPP chemotherapy regimen
4. ^ "MVAC Still the 'Best Treatment' for Advanced Bladder Cancer Patients. 1999". Archived from the original on 2012-01-09. Retrieved 2010-11-18.
5. ^ "Ovarian Cancer Chemotherapy: Know Your Treatment Options".
6. ^ Rodriguez Victorio (1973). "POMP combination chemotherapy of adult acute leukemia". Cancer. 32 (1): 69–75\. doi:10.1002/1097-0142(197307)32:1<69::AID-CNCR2820320109>3.0.CO;2-0. PMID 4515259.
7. ^ Kiesewetter B, Mayerhoefer ME, Lukas J, Zielinski CC, Müllauer L, Raderer M (2014). "Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)". Ann. Hematol. 93 (2): 249–53\. doi:10.1007/s00277-013-1865-3. PMID 23925930. S2CID 12851937.
8. ^ a b c d e Treatment of Wilms Tumor at National Cancer Institute. Last Modified: 03/29/2012
9. ^ El Weshi, A; Memon, M; Raja, M; Bazarbashi, S; Rahal, M; El Foudeh, M; Pai, C; Allam, A; El Hassan, I; Ezzat, A (October 2004). "VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors". American Journal of Clinical Oncology. 27 (5): 529–34\. doi:10.1097/01.coc.0000135815.94162.83. PMID 15596925. S2CID 6362786.
10. ^ Kosmidis, P; Mylonakis, N; Fountzilas, G; Pavlidis, N; Samantas, E; Karabelis, A; Kattis, K; Skarlos, D (July 1996). "A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group". Annals of Oncology. 7 (5): 517–20\. doi:10.1093/oxfordjournals.annonc.a010642. PMID 8839908.

## External links

[edit]

* Chemotherapy regimens and references
* Chemotherapy side effects Archived 2012-08-15 at the Wayback Machine
* Christie Hospital Chemotherapy Patient Information Sheets

* v
* t
* e

Intracellular chemotherapeutic agents / antineoplastic agents (L01)

SPs/MIs
(M phase)|

| Block microtubule assembly|

* Vinca alkaloids (Vinblastine#
* Vincristine#
* Vindesine
* Vinflunine§
* Vinorelbine#)

|

Block microtubule disassembly|

* Taxanes (Cabazitaxel
* Docetaxel#
* Larotaxel
* Ortataxel†
* Paclitaxel#
* Tesetaxel)
* Epothilones (Ixabepilone)

DNA replication
inhibitor|

| DNA precursors/
antimetabolites
(S phase)|

| Folic acid|

* Dihydrofolate reductase inhibitor (Aminopterin
* Methotrexate#
* Pemetrexed
* Pralatrexate)
* Thymidylate synthase inhibitor (Pemetrexed
* Raltitrexed)

|

Purine|

* Adenosine deaminase inhibitor (Pentostatin)

* Halogenated/ribonucleotide reductase inhibitors (Cladribine
* Clofarabine
* Fludarabine)
* Nelarabine
* Rabacfosadine
* Thiopurine (Mercaptopurine#
* Tioguanine#)

Pyrimidine|

* Thymidylate synthase inhibitor (Capecitabine#
* Carmofur
* Doxifluridine
* Floxuridine
* Fluorouracil#
* Tegafur (+gimeracil/oteracil))

* DNA polymerase inhibitor (Cytarabine# +daunorubicin)

* Ribonucleotide reductase inhibitor (Gemcitabine#)

* Hypomethylating agent (Azacitidine
* Decitabine)

Deoxyribonucleotide|

* Ribonucleotide reductase inhibitor (Hydroxycarbamide#)

Topoisomerase inhibitors
(S phase)|

| I|

* Camptotheca (Belotecan
* Camptothecin
* Cositecan†
* Etirinotecan pegol†
* Exatecan
* Gimatecan
* Irinotecan#
* Lurtotecan‡
* Rubitecan‡
* Silatecan§
* Topotecan)

|

II|

* Podophyllum (Etoposide#
* Teniposide)

II+Intercalation|

* Anthracyclines (Aclarubicin
* Amrubicin†
* Daunorubicin# (+cytarabine)
* Doxorubicin#
* Epirubicin
* Idarubicin
* Pirarubicin
* Valrubicin
* Zorubicin)
* Anthracenediones (Losoxantrone
* Mitoxantrone
* Pixantrone)
* Amsacrine
* Bisantrene
* Crisnatol
* Menogaril§

Crosslinking of DNA
(CCNS)|

| Alkylating|

* Nitrogen mustards: Bendamustine#
* Chlormethine
* Cyclophosphamide# (Ifosfamide#
* Trofosfamide)
* Chlorambucil#
* Melphalan (Melphalan flufenamide)
* Prednimustine
* Uramustine

* Nitrosoureas: Carmustine
* Fotemustine
* Lomustine (Semustine)
* Nimustine
* Ranimustine
* Streptozocin

* Alkyl sulfonates: Busulfan (Mannosulfan
* Treosulfan)

* Aziridines: Carboquone
* Thiotepa
* Triaziquone
* Triethylenemelamine

|

Platinum-based|

* Carboplatin#
* Cisplatin#
* Dicycloplatin
* Nedaplatin
* Oxaliplatin#
* Satraplatin

Nonclassical|

* Altretamine
* Hydrazines (Procarbazine#)
* Etoglucid
* Mitobronitol
* Pipobroman
* Triazenes (Dacarbazine#
* Mitozolomide§
* Temozolomide)

Intercalation|

* Streptomyces (Dactinomycin#
* Bleomycin#
* Mitomycins
* Plicamycin)

Photosensitizers/PDT|

* Aminolevulinic acid
* Efaproxiral
* Methyl aminolevulinate
* Padeliporfin
* Porphyrin derivatives (Porfimer sodium
* Talaporfin
* Temoporfin
* Verteporfin)

Other|

| Enzyme inhibitors|

* FI (Tipifarnib§)
* CDK inhibitors (Abemaciclib
* Alvocidib†
* Palbociclib
* Ribociclib
* Seliciclib†)
* PrI
* Bortezomib
* Carfilzomib
* Oprozomib
* Ixazomib
* PhI (Anagrelide)
* IMPDI (Tiazofurin§)
* LI (Masoprocol)
* PARP inhibitor (Fuzuloparib
* Niraparib +abiraterone acetate
* Olaparib
* Rucaparib)
* HDAC (Belinostat
* Entinostat
* Panobinostat
* Romidepsin
* Vorinostat)
* PIKI (Pi3K) (Alpelisib
* Copanlisib‡
* Duvelisib
* Idelalisib
* Inavolisib
* Umbralisib‡)
* IDH (Enasidenib
* Ivosidenib
* Olutasidenib
* Vorasidenib)

|

Receptor antagonists|

* ERA (Atrasentan)
* Retinoid X receptor (Bexarotene)
* Sex steroid (Testolactone)

Other/ungrouped|

* Adagrasib
* Aflibercept
* Arsenic trioxide
* Asparagine depleters (Asparaginase#/Pegaspargase)
* Axicabtagene ciloleucel
* Belzutifan
* Bexarotene
* Brexucabtagene autoleucel
* Celecoxib
* Ciltacabtagene autoleucel
* Demecolcine
* Denileukin diftitox
* Eflornithine
* Elesclomol§
* Elsamitrucin
* Epacadostat
* Eribulin
* Estramustine
* Glasdegib
* Idecabtagene vicleucel
* Imetelstat
* Lifileucel
* Lisocabtagene maraleucel
* Lonidamine
* Lucanthone
* Lurbinectedin
* Mitoguazone
* Mitotane
* Nadofaragene firadenovec
* Navitoclax
* Obecabtagene autoleucel
* Oblimersen†
* Omacetaxine mepesuccinate
* Plitidepsin
* Tabelecleucel
* Retinoids (Alitretinoin
* Tretinoin#)
* Selinexor
* Sitimagene ceradenovec
* Sotorasib
* Tagraxofusp
* Talimogene laherparepvec
* Tazemetostat
* Tebentafusp
* Tiazofurine
* Tigilanol tiglate
* Tisagenlecleucel
* Trabectedin
* Veliparib
* Venetoclax
* Verdinexor
* Vosaroxin

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template